Omnicell

OMCL

Market cap $2.29B

Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026.

6,106 shares were sold for a transaction value of $243,629 on Dec. 3, 2025. The sale represented 5.85% of direct holdings, reducing direct ownership to 98,282 shares (0.2122% of shares outstanding).

PAAS, OMCL and MDB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Dec. 16, 2025.

COF, QCRH, TNET, MDB and OMCL have been added to the Zacks Rank #1 (Strong Buy) List on Dec. 16, 2025.

Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations Transcript

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?

FORT WORTH, Texas--(BUSINESS WIRE)--Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management.

OMCL's expanding SaaS pipeline, global push and solid solvency highlight growth potential despite rising competition.